Modality
mAb
MOA
BCMA ADC
Target
RET
Pathway
Complement
Endometrial CaSchizophreniaPBC
Development Pipeline
Preclinical
Jan 2025
→ Nov 2027
PreclinicalCurrent
NCT05052299
2,441 pts·PBC
2025-01→2027-11·Active
2,441 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-171.6y awayInterim· PBC
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2027-11-17 · 1.6y away
PBC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05052299 | Preclinical | PBC | Active | 2441 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |